评估药代动力学标志物与结局的相关性,并应用于抗体预防效力试验
抗体介导预防效力试验首次评估被动给予广谱中和单克隆抗体能否预防HIV感染,将4600名HIV阴性志愿者随机分配接受10次VRC01单抗或安慰剂输注。次要目标采用两阶段抽样、药代动力学模型和感染时间估计量,评估血清VRC01浓度与HIV感染瞬时率的关系;模拟和类抗体介导预防应用显示,直接法(而非间接法)比Cox模型效力更高,且感染时间估计量的质量对方法性能影响很大。
要点
- 抗体介导预防效力试验将4600名HIV阴性志愿者随机分配接受10次VRC01单抗或安慰剂输注。
- 直接法检查估计感染日期时标志物是否意外偏低,在模拟中比Cox模型效力更高。
- 间接法检查感染病例从最近输注到估计感染日期的时间是否意外长,未显示优于Cox模型。
核心结论
- 直接法(检查标志物在估计感染日期是否意外偏低)在模拟和类抗体介导预防应用中比Cox模型效力更高,而间接法未显示更高效力。
- 感染时间估计量的质量对方法性能影响很大,纳入优化估计量的细节很关键。
研究设计与样本
- 抗体介导预防效力试验将4600名HIV阴性志愿者随机分配接受10次VRC01单抗或安慰剂输注。
- 次要目标采用两阶段抽样设计、时间-浓度曲线的药代动力学模型和HIV感染时间估计量。
- 研究开发了两种以结局状态为条件的方法:间接法和直接法,并与含时变协变量的Cox模型比较。
主要发现
- 在模拟和类抗体介导预防应用中,方法(2)(直接法)比Cox模型效力更高,而方法(1)(间接法)未显示更高效力。
- 感染时间估计量的质量对方法性能影响很大。
局限性
- 标志物的个体间变异相对于个体内变异较低,限制了含时变协变量Cox模型的效力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Antibody Mediated Prevention efficacy trials are the first studies to evaluate whether passive administration of a broadly neutralizing monoclonal antibody can prevent human immunodeficiency virus (HIV) acquisition. The trials randomize 4600 HIV-negative volunteers to receive 10 infusions of the monoclonal antibody VRC01 or placebo. The primary objective compares the incidence of HIV infection between the study groups. The secondary objective assesses whether and how a marker defined as the serum concentration of VRC01 over time associates with the instantaneous rate of HIV infection, using a two-phase sampling design, a pharmacokinetic model for the time-concentration curve, and an estimator of HIV infection times. While a Cox model with a time-dependent covariate constitutes an important approach to this problem, the low interindividual versus intraindividual marker variability limits its power, motivating us to develop two alternative methods that condition on outcome status: (1) an indirect method that checks whether HIV-infected cases have unexpectedly long times from the most recent infusion to the estimated infection date and (2) a direct method that checks whether the marker itself is unexpectedly low at estimated infection dates. In simulations and a pseudo Antibody Mediated Prevention application, we find that method (2) (but not (1)) has greater power than the Cox model. We also find that the quality of the infection time estimator majorly impacts method performance, and thus, incorporating details of an optimized estimator is critical. The methods apply more generally for assessing a time-dependent longitudinal marker as a correlate of risk when the marker trajectory is modeled pharmacokinetically.
引用
- Gilbert PB, Zhang Y, Rudnicki E, et al. Assessing pharmacokinetic marker correlates of outcome, with application to antibody prevention efficacy trials. Stat Med. 2019. PMID: 31313349. doi:10.1002/sim.8310
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。